- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02005068
Ceftaroline in the Treatment of Bone and Joint Infections
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Florida
-
Orlando, Florida, United States, 32806
- Orlando Regional Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Adults > 18 years of age with the following osteoarticular infections:
Infected prosthetic knee or hip (first or second episode) with 2 stage procedure planned.
Criteria for infected joint:
- Sinus tract which communicates with the joint
- Preoperative diagnosis by diagnostic, culture positive arthrocentesis
- Intraoperative diagnosis-evidence of purulence/inflammation is seen by the surgeon and/or the pathologist, and at least 2 intraoperative samples grow the same organism (only 1 needed if S. aureus) OR
Acute osteomyelitis of an extremity Criteria for acute osteomyelitis (all 4 needed)
- Onset less than 4 weeks prior to evaluation
- Radiographic (plain, MRI, TC) evidence of osteomyelitis
- Positive culture from bone or blood culture with organism known to cause osteomyelitis
- Orthopedic consultant must concur with diagnosis. PLUS: Positive bone/joint or blood culture for an organism known to cause osteomyelitis which is Ceftaroline susceptible
Exclusion criteria:
Immunocompromised hosts:
- AIDS/HIV patients
- Cancer requiring ongoing chemotherapy or radiation therapy steroid on an ongoing basis.
- Any condition requiring > 20 mg prednisone or equivalent
- TNF (tumor necrosing factor) inhibitor use (ongoing)
- Organ transplant list
- Diabetic foot infections
- Osteomyelitis in association with decubitus ulcers
- Vertebral osteomyelitis/spinal epidural abscess
- Septic bursitis
- Gonococcal arthritis
- Ceftaroline nonsusceptible organisms isolated from bone, joint or blood.
- Infected external fixation devices
- Calculated creatinine clearance < 50 mL/min at baseline
- History of severe penicillin/B lactam allergy (ID to evaluate)
- Intravenous drug use - lifetime exclusion
- Patients with a nail puncture wound to foot
- Patients at high risk for MDR (multidrug resistant) Gram negative organisms
Please note the use of antibiotic containing cement is not exclusion, as it represents standard of care in some of the infections to be studied
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Acute Osteomyelitis - Non MRSA
For treatment of Acute osteomyelitis (< 6 months duration) Non MRSA isolate- Ceftaroline 600 MG (milligram) IV (intra-venous) every 8 hours for 6 weeks.
|
The duration of treatment will vary based on type of infection (acute osteomyelitis or joint infection) and if MRSA positive or negative.
Other Names:
|
Experimental: Acute osteomyelitis MRSA isolate
For treatment of Acute osteomyelitis (< 6 months duration) MRSA isolate- Ceftaroline 600 MG IV every 8 hours for 8 weeks.
|
The duration of treatment will vary based on type of infection (acute osteomyelitis or joint infection) and if MRSA positive or negative.
Other Names:
|
Experimental: Prosthetic joint infection
For treatment of prosthetic joint infection Ceftaroline 600 mg IV every 8 hours for 6 weeks.
|
The duration of treatment will vary based on type of infection (acute osteomyelitis or joint infection) and if MRSA positive or negative.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sustained clinical remission from the treated osteoarticular infection
Time Frame: 1 year after study drug completion
|
Sustained clinical remission is defined by the absence of either clinical or microbiological evidence of failure at 1 year after study drug completion, in patients who complete the protocol's antibiotic regimen(s) and did not require subsequent antibiotics for their osteoarticular infection beyond the protocol prescribed regimen.
|
1 year after study drug completion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Initial clinical success from the treated osteoarticular infection
Time Frame: 30 days after conclusion of study antibiotic
|
Initial clinical success will be measured by the agreement of the Infectious disease consultant and Orthopedic surgeon that the patient has had a positive response to therapy.
Success will be measured by decrease of CRP (C reactive protein) by 50% from baseline if initially elevated, no evidence of drainage, sinus tract formation or infection related bone instability.
Follow up cultures, if available are negative for originally isolated organism.
In patients with prothetic joints no new warmth, tenderness or inflammation.
|
30 days after conclusion of study antibiotic
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with defined symptoms, signs and lab values as markers of safety and tolerance.
Time Frame: Day one through one year after completion of study drug.
|
Symptoms will be assessed daily by study team while patient is hospitalized and reviewed weekly by investigator while the patient is receiving study drug.
Specific symptoms will include fever, chills, rash, nausea.
diarrhea, abdominal pain, pain at the surgical/infection site, vertigo, shortness of breath, hives or other rash.
A baseline physical will be performed on enrollment and repeated each week at follow up visits.
Labs will checked at baseline, then daily through hospitalization and then weekly.
If patient develops persistent diarrhea a stool test for C. Diff PCR (polymerase chain reaction) will be performed.
|
Day one through one year after completion of study drug.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mark R. Wallace, MD, Orlando Health
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TEF-IT-17
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteomyelitis
-
Seattle Children's HospitalMansoura University; Boston Children's Hospital, Boston, MA, USA; Hospital for... and other collaboratorsRecruitingChronic Recurrent Multifocal Osteomyelitis | Chronic Nonbacterial OsteomyelitisUnited States
-
Rigshospitalet, DenmarkRecruitingOsteomyelitis; VertebraDenmark
-
University of LouisvilleOsteo Science FoundationNot yet recruitingOsteomyelitis of JawUnited States
-
Asan Medical CenterCompletedVertebral OsteomyelitisKorea, Republic of
-
Hospices Civils de LyonRecruiting
-
Cubist Pharmaceuticals LLCCompleted
-
Hospices Civils de LyonCompletedOsteomyelitis | Hematogenous Osteomyelitis RelapseFrance
-
Seattle Children's HospitalUniversity of WashingtonRecruitingChronic Recurrent Multifocal OsteomyelitisUnited States
-
Charite University, Berlin, GermanyUnknownSurgical Procedure, Unspecified | Vertebral Osteomyelitis | SpondylodiscitisGermany
-
Nantes University HospitalCompletedVertebral Osteomyelitis | SpondylodiscitisFrance
Clinical Trials on Ceftaroline
-
Forest LaboratoriesCompleted
-
Children's Hospital Medical Center, CincinnatiActive, not recruitingCystic FibrosisUnited States
-
Basim AsmarForest LaboratoriesUnknownVentriculoperitoneal Shunt | Cerebrospinal Fluid ShuntsUnited States
-
Baylor College of MedicineAllerganCompletedCeftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in ChildrenOsteomyelitis | Bone Infection | Hematogenously Acquired Staphylococcus Aureus OsteomyelitisUnited States
-
Poitiers University HospitalCompleted
-
Albany Medical CollegeForest Laboratories; Albany College of Pharmacy and Health SciencesCompletedCommunity Acquired Bacterial PneumoniaUnited States
-
Forest LaboratoriesCompletedBacterial InfectionUnited States
-
Medical University of ViennaRecruitingInfection During Renal Replacement TherapyAustria
-
PfizerCompleted
-
PfizerForest LaboratoriesCompleted